Format

Send to

Choose Destination
See comment in PubMed Commons below
J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1209-13. doi: 10.1136/jnnp-2013-306789. Epub 2014 Mar 17.

Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients.

Author information

1
The Department of Medicine, University of Melbourne, Parkville, Victoria, Australia Melbourne Brain Centre, Royal Melbourne Hospital, Parkville, Victoria, Australia.
2
Department of Radiology, Xuanwu Hospital Capital Medical University, Beijing, China.
3
Bio21 Institute, University of Melbourne, Parkville, Victoria, Australia.
4
Eastern Clinical Research Unit Box-Hill Hospital, Victoria, Australia.
5
Bio21 Institute, University of Melbourne, Parkville, Victoria, Australia Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Victoria, Australia.
6
The Department of Medicine, University of Melbourne, Parkville, Victoria, Australia.
7
Department of Neuroimmunology, UCL institute of Neurology, London, UK.
8
National Centre for Epidemiology and Population Health, College of Medicine, Biology and Environment, Australian National University, Canberra, Australian Capital Territory, Australia.
9
Melbourne Brain Centre, Royal Melbourne Hospital, Parkville, Victoria, Australia.
10
Eastern Clinical Research Unit Box-Hill Hospital, Victoria, Australia MRI services, MIA, Box Hill, Victoria, Australia.
11
The Menzies Research Institute, University of Tasmania, Hobart, Tasmania, Australia.
12
Department of Neuroscience, McKnight Brain Institute, University of Florida, Gainesville, Florida, USA EnCor Biotechnology Inc. Gainesville, Florida.
13
The Department of Medicine, University of Melbourne, Parkville, Victoria, Australia Melbourne Brain Centre, Royal Melbourne Hospital, Parkville, Victoria, Australia Eastern Clinical Research Unit Box-Hill Hospital, Victoria, Australia.

Abstract

OBJECTIVES:

We evaluated whether the measurement of serum phosphorylated neurofilament heavy chain (pNF-H) titre is likely to be a valid biomarker of axonal injury in multiple sclerosis (MS).

METHODS:

Serum pNF-H concentrations were measured by ELISA in cases with relapsing-remitting (RR)-MS (n=81), secondary progressive (SP) MS (n=13) and primary progressive (PP)-MS; n=6) MS; first demyelinating event (FDE; n=82); and unaffected controls (n=135). A subset of MS cases (n=45) were re-sampled on one or multiple occasions. The Multiple Sclerosis Severity Score (MSSS) and MRI measures were used to evaluate associations between serum pNF-H status, disease severity and cerebral lesion load and activity.

RESULTS:

We confirmed the presence of pNF-H peptides in serum by ELISA. We showed that a high serum pNF-H titre was detectable in 9% of RR-MS and FDE cases, and 38.5% of SP-MS cases. Patients with a high serum pNF-H titre had higher average MSSS scores and T2 lesion volumes than patients with a low serum pNF-H titre. Repeated sampling of a subset of MS cases showed that pNF-H levels can fluctuate over time, likely reflecting temporal dynamics of axonal injury in MS.

CONCLUSIONS:

A subset of FDE/MS cases was found to have a high serum pNF-H titre, and this was associated with changes in clinical outcome measures. We propose that routine measurement of serum pNF-H should be further investigated for monitoring axonal injury in MS.

KEYWORDS:

MULTIPLE SCLEROSIS

PMID:
24639436
DOI:
10.1136/jnnp-2013-306789
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center